T1	Participants 864 1046	50 eligible patients (aged â‰¥12 years) with homozygous familial hypercholesterolaemia, on stable lipid-regulating therapy for at least 4 weeks, and not receiving lipoprotein apheresis
T2	Participants 1840 2025	50 eligible patients randomly assigned to the two treatment groups, 49 actually received the study drug and completed the study (16 in the placebo group and 33 in the evolocumab group).
T3	Participants 745 862	phase 3 trial was undertaken at 17 sites in ten countries in North America, Europe, the Middle East, and South Africa
